CR9904A - Compuestos que tienen actividad en el receptor M1 y sus usos en medicina - Google Patents

Compuestos que tienen actividad en el receptor M1 y sus usos en medicina

Info

Publication number
CR9904A
CR9904A CR9904A CR9904A CR9904A CR 9904 A CR9904 A CR 9904A CR 9904 A CR9904 A CR 9904A CR 9904 A CR9904 A CR 9904A CR 9904 A CR9904 A CR 9904A
Authority
CR
Costa Rica
Prior art keywords
compounds
alkyl
fluorine atoms
substituted
receptor
Prior art date
Application number
CR9904A
Other languages
English (en)
Inventor
Brian Budzik
David Gwyn Cooper
Ian Thomson Forbes
Vincenzo Garzya
Jian Jin
Dongchuan Shi
Paul William Smith
Graham Walker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519950.0A external-priority patent/GB0519950D0/en
Priority claimed from GB0602040A external-priority patent/GB0602040D0/en
Application filed filed Critical
Publication of CR9904A publication Critical patent/CR9904A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se proporcionan compuestos de formula (I), sales y solvatos, donde R4 es fluor, R5 se selecciona entre hidrogeno, halogeno, ciano, alquilo C1-6, alquilo C1-6 sustituido con uno o mas atomos de fluor, alcoxi C1-6 sustituido con uno o mas atomos de fluor; y R6 se selecciona entre halogeno, ciano, alquilo c1-6, alquilo c1-6 sustituido con uno o mas atomos de fluor, cicloalquilo C3-6, cicloalquilo C3-6 sustituido con uno o mas atomos de fluor, alcoxi C1-6 y alcoxi C1-6 sustituido con uno o mas atomos de fluor, y Q es hidrogeno o alquilo C1-6. Se espera que los compuestos sean utiles para terapia, por ejemplo en el tratamiento de trastornos psicoticos y alteraciones cognitivas.
CR9904A 2005-09-30 2008-04-18 Compuestos que tienen actividad en el receptor M1 y sus usos en medicina CR9904A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0519950.0A GB0519950D0 (en) 2005-09-30 2005-09-30 Compounds
GB0602040A GB0602040D0 (en) 2006-02-01 2006-02-01 Compounds

Publications (1)

Publication Number Publication Date
CR9904A true CR9904A (es) 2008-07-29

Family

ID=37598231

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9904A CR9904A (es) 2005-09-30 2008-04-18 Compuestos que tienen actividad en el receptor M1 y sus usos en medicina

Country Status (24)

Country Link
US (2) US8283364B2 (es)
EP (1) EP1943230B1 (es)
JP (1) JP5209480B2 (es)
KR (2) KR101374458B1 (es)
CN (1) CN101321736B (es)
AR (1) AR056103A1 (es)
AT (1) ATE492537T1 (es)
AU (1) AU2006296369B2 (es)
BR (1) BRPI0616609A2 (es)
CA (1) CA2624504C (es)
CR (1) CR9904A (es)
DE (1) DE602006019119D1 (es)
EA (1) EA016286B1 (es)
IL (1) IL190219A (es)
JO (1) JO2634B1 (es)
MA (1) MA29849B1 (es)
MY (1) MY148504A (es)
NO (1) NO20081945L (es)
NZ (1) NZ566508A (es)
PE (1) PE20070490A1 (es)
TW (1) TWI389905B (es)
UA (1) UA101299C2 (es)
WO (1) WO2007036715A2 (es)
ZA (1) ZA200802167B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5209479B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類
EA016286B1 (ru) 2005-09-30 2012-03-30 Глэксо Груп Лимитед Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
JP5209481B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用
US7766829B2 (en) * 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
WO2009124882A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists
GB0817982D0 (en) 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
JP2017533227A (ja) * 2014-11-03 2017-11-09 ウィリアム・ボーモント・ホスピタルＷｉｌｌｉａｍ Ｂｅａｕｍｏｎｔ Ｈｏｓｐｉｔａｌ 低活動膀胱症候群を治療するための方法
KR20170140382A (ko) 2015-04-29 2017-12-20 얀센 파마슈티카 엔.브이. 아자벤즈이미다졸 및 ampa 수용체 조절제로서의 이의 용도
CN107750250B (zh) * 2015-04-29 2021-09-07 詹森药业有限公司 吲哚酮化合物及其作为ampa受体调节剂的用途
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CN107673994A (zh) * 2017-04-27 2018-02-09 联化科技股份有限公司 一种芳基甲烷类化合物的制备方法
CN107739342B (zh) * 2017-11-29 2020-01-10 华南理工大学 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法
CN117049938B (zh) * 2023-06-20 2024-06-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3989707A (en) * 1974-06-21 1976-11-02 Janssen Pharmaceutica N.V. Benzimidazolinone derivatives
US4292321A (en) 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
DE3124366A1 (de) 1981-06-20 1982-12-30 Hoechst Ag, 6000 Frankfurt N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
DE4040300A1 (de) 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
JP3916093B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 光学活性イミダゾリジノン誘導体とその製造方法
CA2200468A1 (en) * 1994-10-27 1996-05-09 Wayne J. Thompson Muscarine antagonists
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
US5574044A (en) 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
AU7478396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine agonists
US5718912A (en) 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO1999032481A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO2001027104A1 (en) 1999-10-13 2001-04-19 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
EP1263754A1 (en) 2000-02-01 2002-12-11 Millennium Pharmaceuticals, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
WO2002085361A1 (en) 2001-04-18 2002-10-31 Euro-Celtique, S.A. Benzimidazolone compounds
CA2444595A1 (en) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
CA2457647A1 (en) 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Benzimidazolidinone derivatives as muscarinic agents
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
DK1491212T3 (da) 2002-03-29 2012-10-29 Mitsubishi Tanabe Pharma Corp Middel til behandling af søvnforstyrrelser
JP2005532361A (ja) 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
AU2003300902A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Piperidine derivatives as CCR5 antagonists
JP2005102133A (ja) 2003-04-28 2005-04-14 Ricoh Co Ltd 画像形成装置及び宛先情報参照方法
AU2004259739A1 (en) 2003-07-23 2005-02-03 Wyeth Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands
ATE539077T1 (de) 2003-09-03 2012-01-15 Pfizer Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor
ATE417830T1 (de) 2004-11-02 2009-01-15 Pfizer Sulfonylbenzimidazolderivate
US7300947B2 (en) 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
JP5209481B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用
EA016286B1 (ru) 2005-09-30 2012-03-30 Глэксо Груп Лимитед Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
JP5209479B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類
BRPI0716602A2 (pt) 2006-09-08 2013-09-17 Gillette Co escova de dentes com méltiplos estados de cerda
GB0706164D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706188D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706189D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706190D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706187D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706173D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
MA29849B1 (fr) 2008-10-03
AR056103A1 (es) 2007-09-19
NO20081945L (no) 2008-06-04
ZA200802167B (en) 2009-08-26
JP5209480B2 (ja) 2013-06-12
PE20070490A1 (es) 2007-05-30
JP2009512635A (ja) 2009-03-26
KR20080049090A (ko) 2008-06-03
DE602006019119D1 (de) 2011-02-03
AU2006296369A1 (en) 2007-04-05
TWI389905B (zh) 2013-03-21
KR101374458B1 (ko) 2014-03-17
CA2624504C (en) 2014-07-08
US20080058378A1 (en) 2008-03-06
EP1943230A2 (en) 2008-07-16
AU2006296369B2 (en) 2012-12-20
BRPI0616609A2 (pt) 2011-06-28
US8481566B2 (en) 2013-07-09
NZ566508A (en) 2011-07-29
CN101321736B (zh) 2012-04-04
US20080255195A1 (en) 2008-10-16
CA2624504A1 (en) 2007-04-05
ATE492537T1 (de) 2011-01-15
US8283364B2 (en) 2012-10-09
WO2007036715A2 (en) 2007-04-05
EA200801001A1 (ru) 2008-08-29
CN101321736A (zh) 2008-12-10
MY148504A (en) 2013-04-30
WO2007036715A3 (en) 2007-05-18
JO2634B1 (en) 2012-06-17
IL190219A (en) 2012-10-31
IL190219A0 (en) 2008-11-03
EP1943230B1 (en) 2010-12-22
EA016286B1 (ru) 2012-03-30
TW200806657A (en) 2008-02-01
KR20130091791A (ko) 2013-08-19
UA101299C2 (uk) 2013-03-25

Similar Documents

Publication Publication Date Title
CR9904A (es) Compuestos que tienen actividad en el receptor M1 y sus usos en medicina
CR10314A (es) Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina
CL2020000367A1 (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
ECSP045315A (es) MIMÉTICOS DE GlucocorticoidES, PROCEDIMIENTOS PARA SU PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS Y USOS DE LOS MISMOS
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
CY1108451T1 (el) Παραγωγα τριαζολυλοτροπανιου ως ρυθμιστες ccr5
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CL2007002450A1 (es) Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03).
CR9881A (es) Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos
AR071385A1 (es) Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia.
AR036608A1 (es) Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad
SV2005002099A (es) " nuevos compuestos " ref. pc 32096a
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
AR074352A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica.
ECSP11010901A (es) Compuestos de amida útiles en terapia
AR086036A1 (es) DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5)
WO2007036718A3 (en) Compounds which have activity at m1 receptor and their uses in medicine
CR9155A (es) PIRAZOLO (3,4-b) PIRIDINAS E INDAZOLES TERAPEUTICOS
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
ECSP088602A (es) Compuestos con efectos medicinales debido a la interacción con el receptor de glucocorticoides
AR041898A1 (es) Derivados de 4(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales
AR065864A1 (es) Compuesto de oxi-ciclohexil-piperidinil-dihidro-benzimidazol-2-ona composicion farmacetica que lo comprende su uso para la preparacion de un medicamento y compuestos intermediarios para su preparacion
CL2004000730A1 (es) Compuestos derivados de 4-[2-(fenilsulfanil sustituido)fenil]-1,2,3,6-tetrahidropiridina; composicion farmaceutica que los contiene; y su uso para el tratamiento de trastornos afectivos, tales como la depresion, trastornos de ansiedad, de ansiedad so
AR085276A1 (es) Antagonistas de p2x7r y su uso
PE20110406A1 (es) Moduladores de los canales de iones de calcio y sus usos